PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30222798-0	2018	Letter to the Editor: Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for DME Refractory to Anti-VEGF Therapy: Meta-Analysis and Clinical Implications.	dimethylethylsilylimidazole	95-98	vascular endothelial growth factor A	Homo sapiens	118-122	
27195370-2	2011	Avastin (bevacizumab), another anti-VEGF, is available as an anti-cancer agent and is being used to treat DME without an indication for this use.	dimethylethylsilylimidazole	106-109	vascular endothelial growth factor A	Homo sapiens	36-40	
28484955-2	2017	Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME.	dimethylethylsilylimidazole	148-151	vascular endothelial growth factor A	Homo sapiens	46-50	
28484955-3	2017	Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment.	dimethylethylsilylimidazole	71-74	vascular endothelial growth factor A	Homo sapiens	40-44	
28484955-4	2017	The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges.	dimethylethylsilylimidazole	139-142	vascular endothelial growth factor A	Homo sapiens	99-103	
28484955-6	2017	Although a significant body of research is directed towards other molecules that could potentially be new therapeutic targets, VEGF inhibition is expected to play an important long-term role in the treatment of DME considering the pathogenesis of the disease.	dimethylethylsilylimidazole	211-214	vascular endothelial growth factor A	Homo sapiens	127-131	
25812378-2	2015	New pharmacological approaches based on the use of intravitreal drugs, such as corticosteroids and anti-vascular endothelial growth factor, have recently been developed for the treatment of DME.	dimethylethylsilylimidazole	190-193	vascular endothelial growth factor A	Homo sapiens	104-138	
24339679-4	2013	DME is treated with laser photocoagulation and/or intra- vitreal injection of anti-vascular endothelial growth factor (VEGF) agents or steroids.	dimethylethylsilylimidazole	0-3	vascular endothelial growth factor A	Homo sapiens	78-117	
24339679-4	2013	DME is treated with laser photocoagulation and/or intra- vitreal injection of anti-vascular endothelial growth factor (VEGF) agents or steroids.	dimethylethylsilylimidazole	0-3	vascular endothelial growth factor A	Homo sapiens	119-123	
22523648-4	2012	The introduction of anti-VEGF drugs brought a revolutionary change in the treatment of DME.	dimethylethylsilylimidazole	87-90	vascular endothelial growth factor A	Homo sapiens	25-29	
22132316-3	2012	The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs.	dimethylethylsilylimidazole	65-68	vascular endothelial growth factor A	Homo sapiens	130-134	
35411193-1	2022	Background: Anti-vascular endothelial growth factor (anti-VEGF) medicines have revolutionized DME and DR treatment.	dimethylethylsilylimidazole	94-97	vascular endothelial growth factor A	Homo sapiens	58-62	
35411193-16	2022	Conclusion: Both anti-VEGF medications are effective in treating DME, Lucentis showed better improvements in BCVA and macular thickness than Avastin.	dimethylethylsilylimidazole	65-68	vascular endothelial growth factor A	Homo sapiens	22-26	
33253664-1	2021	PURPOSE: To describe longitudinal retinal fluid dynamics on spectral domain OCT and to identify imaging biomarkers that predict the worsening of DME with interval extension during anti-vascular endothelial growth factor (VEGF) therapy.	dimethylethylsilylimidazole	145-148	vascular endothelial growth factor A	Homo sapiens	221-225	
32927780-3	2020	This study investigated miRNAs as a biomarker to predict treatment response to anti-VEGF in DME.	dimethylethylsilylimidazole	92-95	vascular endothelial growth factor A	Homo sapiens	84-88